nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—Protein Kinase Inhibitors—Vandetanib—thyroid cancer	0.565	1	CiPCiCtD
Everolimus—kidney cancer—thyroid cancer	0.333	1	CtDrD
Everolimus—MTOR—neck—thyroid cancer	0.000757	0.212	CbGeAlD
Everolimus—FKBP1A—neck—thyroid cancer	0.000681	0.191	CbGeAlD
Everolimus—FKBP1A—trachea—thyroid cancer	0.00041	0.115	CbGeAlD
Everolimus—MTOR—thyroid gland—thyroid cancer	0.00036	0.101	CbGeAlD
Everolimus—FKBP1A—thyroid gland—thyroid cancer	0.000324	0.0909	CbGeAlD
Everolimus—MTOR—head—thyroid cancer	0.00032	0.0897	CbGeAlD
Everolimus—FKBP1A—head—thyroid cancer	0.000288	0.0806	CbGeAlD
Everolimus—MTOR—lymph node—thyroid cancer	0.000224	0.0628	CbGeAlD
Everolimus—FKBP1A—lymph node—thyroid cancer	0.000201	0.0565	CbGeAlD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	4.46e-05	0.00158	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—AKT1—thyroid cancer	4.45e-05	0.00158	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MEN1—thyroid cancer	4.45e-05	0.00157	CbGpPWpGaD
Everolimus—MTOR—TSH signaling pathway—AKT1—thyroid cancer	4.4e-05	0.00156	CbGpPWpGaD
Everolimus—MTOR—mTOR signaling pathway—AKT1—thyroid cancer	4.4e-05	0.00156	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—NRAS—thyroid cancer	4.37e-05	0.00155	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—BRAF—thyroid cancer	4.36e-05	0.00154	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—NRAS—thyroid cancer	4.34e-05	0.00153	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—HIF1A—thyroid cancer	4.32e-05	0.00153	CbGpPWpGaD
Everolimus—MTOR—Costimulation by the CD28 family—AKT1—thyroid cancer	4.3e-05	0.00152	CbGpPWpGaD
Everolimus—MTOR—Regulation of Telomerase—AKT1—thyroid cancer	4.3e-05	0.00152	CbGpPWpGaD
Everolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—HRAS—thyroid cancer	4.27e-05	0.00151	CbGpPWpGaD
Everolimus—MTOR—AMPK Signaling—AKT1—thyroid cancer	4.25e-05	0.0015	CbGpPWpGaD
Everolimus—MTOR—SREBP signalling—AKT1—thyroid cancer	4.25e-05	0.0015	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—PTEN—thyroid cancer	4.16e-05	0.00147	CbGpPWpGaD
Everolimus—Renal impairment—Doxorubicin—thyroid cancer	4.15e-05	0.000591	CcSEcCtD
Everolimus—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	4.09e-05	0.00145	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—CCND1—thyroid cancer	4.08e-05	0.00144	CbGpPWpGaD
Everolimus—MTOR—IRS-mediated signalling—HRAS—thyroid cancer	4.07e-05	0.00144	CbGpPWpGaD
Everolimus—Asthenia—Sorafenib—thyroid cancer	4.07e-05	0.00058	CcSEcCtD
Everolimus—Cardiac arrest—Epirubicin—thyroid cancer	4.06e-05	0.000578	CcSEcCtD
Everolimus—MTOR—ErbB1 downstream signaling—KRAS—thyroid cancer	4.04e-05	0.00143	CbGpPWpGaD
Everolimus—Hypoglycaemia—Doxorubicin—thyroid cancer	4.04e-05	0.000576	CcSEcCtD
Everolimus—Cardiac failure—Doxorubicin—thyroid cancer	4.04e-05	0.000576	CcSEcCtD
Everolimus—Lethargy—Doxorubicin—thyroid cancer	4.03e-05	0.000574	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—CALCB—thyroid cancer	4.02e-05	0.00142	CbGpPWpGaD
Everolimus—Pruritus—Sorafenib—thyroid cancer	4.01e-05	0.000572	CcSEcCtD
Everolimus—Blood creatinine increased—Epirubicin—thyroid cancer	4e-05	0.00057	CcSEcCtD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—KRAS—thyroid cancer	3.98e-05	0.00141	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—PTEN—thyroid cancer	3.98e-05	0.00141	CbGpPWpGaD
Everolimus—MTOR—Leptin signaling pathway—AKT1—thyroid cancer	3.97e-05	0.00141	CbGpPWpGaD
Everolimus—Dehydration—Epirubicin—thyroid cancer	3.97e-05	0.000565	CcSEcCtD
Everolimus—Hyponatraemia—Doxorubicin—thyroid cancer	3.96e-05	0.000565	CcSEcCtD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	3.96e-05	0.0014	CbGpPWpGaD
Everolimus—MTOR—IRS-related events—HRAS—thyroid cancer	3.96e-05	0.0014	CbGpPWpGaD
Everolimus—Pain in extremity—Doxorubicin—thyroid cancer	3.95e-05	0.000563	CcSEcCtD
Everolimus—MTOR—Integrated Breast Cancer Pathway—PTEN—thyroid cancer	3.94e-05	0.00139	CbGpPWpGaD
Everolimus—Liver function test abnormal—Epirubicin—thyroid cancer	3.94e-05	0.000561	CcSEcCtD
Everolimus—MTOR—IRS-related events triggered by IGF1R—HRAS—thyroid cancer	3.92e-05	0.00139	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—PTEN—thyroid cancer	3.92e-05	0.00139	CbGpPWpGaD
Everolimus—Dry skin—Epirubicin—thyroid cancer	3.91e-05	0.000557	CcSEcCtD
Everolimus—Abdominal pain upper—Epirubicin—thyroid cancer	3.9e-05	0.000555	CcSEcCtD
Everolimus—Migraine—Doxorubicin—thyroid cancer	3.88e-05	0.000554	CcSEcCtD
Everolimus—Hypokalaemia—Epirubicin—thyroid cancer	3.88e-05	0.000553	CcSEcCtD
Everolimus—Diarrhoea—Sorafenib—thyroid cancer	3.88e-05	0.000553	CcSEcCtD
Everolimus—Breast disorder—Epirubicin—thyroid cancer	3.85e-05	0.000549	CcSEcCtD
Everolimus—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	3.84e-05	0.000548	CcSEcCtD
Everolimus—MTOR—IGF1R signaling cascade—HRAS—thyroid cancer	3.82e-05	0.00135	CbGpPWpGaD
Everolimus—MTOR—Insulin receptor signalling cascade—HRAS—thyroid cancer	3.82e-05	0.00135	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TRIM33—thyroid cancer	3.81e-05	0.00135	CbGpPWpGaD
Everolimus—Nasopharyngitis—Epirubicin—thyroid cancer	3.81e-05	0.000544	CcSEcCtD
Everolimus—Gastritis—Epirubicin—thyroid cancer	3.77e-05	0.000538	CcSEcCtD
Everolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—AKT1—thyroid cancer	3.77e-05	0.00133	CbGpPWpGaD
Everolimus—Alanine aminotransferase increased—Epirubicin—thyroid cancer	3.76e-05	0.000536	CcSEcCtD
Everolimus—Muscular weakness—Epirubicin—thyroid cancer	3.76e-05	0.000536	CcSEcCtD
Everolimus—MTOR—Signaling by VEGF—KRAS—thyroid cancer	3.76e-05	0.00133	CbGpPWpGaD
Everolimus—MTOR—Insulin Signaling—PTEN—thyroid cancer	3.76e-05	0.00133	CbGpPWpGaD
Everolimus—Cardiac arrest—Doxorubicin—thyroid cancer	3.75e-05	0.000535	CcSEcCtD
Everolimus—Dizziness—Sorafenib—thyroid cancer	3.75e-05	0.000535	CcSEcCtD
Everolimus—MTOR—Downstream signal transduction—PTEN—thyroid cancer	3.74e-05	0.00132	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—KRAS—thyroid cancer	3.73e-05	0.00132	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—PTEN—thyroid cancer	3.72e-05	0.00132	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—PTEN—thyroid cancer	3.72e-05	0.00132	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—NRAS—thyroid cancer	3.71e-05	0.00131	CbGpPWpGaD
Everolimus—Abdominal distension—Epirubicin—thyroid cancer	3.71e-05	0.000529	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB2—PTEN—thyroid cancer	3.7e-05	0.00131	CbGpPWpGaD
Everolimus—Blood creatinine increased—Doxorubicin—thyroid cancer	3.7e-05	0.000527	CcSEcCtD
Everolimus—MTOR—DAP12 signaling—PTEN—thyroid cancer	3.69e-05	0.0013	CbGpPWpGaD
Everolimus—Dysphagia—Epirubicin—thyroid cancer	3.69e-05	0.000525	CcSEcCtD
Everolimus—Influenza—Epirubicin—thyroid cancer	3.69e-05	0.000525	CcSEcCtD
Everolimus—Dehydration—Doxorubicin—thyroid cancer	3.67e-05	0.000523	CcSEcCtD
Everolimus—Liver function test abnormal—Doxorubicin—thyroid cancer	3.64e-05	0.000519	CcSEcCtD
Everolimus—MTOR—Disease—TCF7L1—thyroid cancer	3.63e-05	0.00129	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—PTEN—thyroid cancer	3.63e-05	0.00129	CbGpPWpGaD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—AKT1—thyroid cancer	3.63e-05	0.00128	CbGpPWpGaD
Everolimus—MTOR—CXCR4-mediated signaling events—AKT1—thyroid cancer	3.63e-05	0.00128	CbGpPWpGaD
Everolimus—Dry skin—Doxorubicin—thyroid cancer	3.62e-05	0.000516	CcSEcCtD
Everolimus—Pancreatitis—Epirubicin—thyroid cancer	3.61e-05	0.000515	CcSEcCtD
Everolimus—Vomiting—Sorafenib—thyroid cancer	3.61e-05	0.000514	CcSEcCtD
Everolimus—Abdominal pain upper—Doxorubicin—thyroid cancer	3.6e-05	0.000514	CcSEcCtD
Everolimus—MTOR—Senescence and Autophagy in Cancer—TP53—thyroid cancer	3.59e-05	0.00127	CbGpPWpGaD
Everolimus—Hypokalaemia—Doxorubicin—thyroid cancer	3.59e-05	0.000512	CcSEcCtD
Everolimus—Angina pectoris—Epirubicin—thyroid cancer	3.59e-05	0.000512	CcSEcCtD
Everolimus—Rash—Sorafenib—thyroid cancer	3.58e-05	0.00051	CcSEcCtD
Everolimus—Dermatitis—Sorafenib—thyroid cancer	3.57e-05	0.000509	CcSEcCtD
Everolimus—Breast disorder—Doxorubicin—thyroid cancer	3.57e-05	0.000508	CcSEcCtD
Everolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—AKT1—thyroid cancer	3.56e-05	0.00126	CbGpPWpGaD
Everolimus—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	3.55e-05	0.000507	CcSEcCtD
Everolimus—Headache—Sorafenib—thyroid cancer	3.55e-05	0.000507	CcSEcCtD
Everolimus—MTOR—Downstream signaling of activated FGFR—NRAS—thyroid cancer	3.55e-05	0.00126	CbGpPWpGaD
Everolimus—Bronchitis—Epirubicin—thyroid cancer	3.55e-05	0.000505	CcSEcCtD
Everolimus—FKBP1A—Disease—CALCA—thyroid cancer	3.54e-05	0.00125	CbGpPWpGaD
Everolimus—Nasopharyngitis—Doxorubicin—thyroid cancer	3.53e-05	0.000503	CcSEcCtD
Everolimus—Pancytopenia—Epirubicin—thyroid cancer	3.5e-05	0.000499	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB4—NRAS—thyroid cancer	3.5e-05	0.00124	CbGpPWpGaD
Everolimus—Gastritis—Doxorubicin—thyroid cancer	3.49e-05	0.000498	CcSEcCtD
Everolimus—Muscular weakness—Doxorubicin—thyroid cancer	3.48e-05	0.000496	CcSEcCtD
Everolimus—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	3.48e-05	0.000496	CcSEcCtD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—PTEN—thyroid cancer	3.47e-05	0.00123	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—PTEN—thyroid cancer	3.47e-05	0.00123	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—PTEN—thyroid cancer	3.47e-05	0.00123	CbGpPWpGaD
Everolimus—Dysuria—Epirubicin—thyroid cancer	3.45e-05	0.000491	CcSEcCtD
Everolimus—Neutropenia—Epirubicin—thyroid cancer	3.45e-05	0.000491	CcSEcCtD
Everolimus—MTOR—Senescence and Autophagy in Cancer—HRAS—thyroid cancer	3.44e-05	0.00122	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—HRAS—thyroid cancer	3.44e-05	0.00122	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—PTEN—thyroid cancer	3.44e-05	0.00122	CbGpPWpGaD
Everolimus—Abdominal distension—Doxorubicin—thyroid cancer	3.43e-05	0.000489	CcSEcCtD
Everolimus—Upper respiratory tract infection—Epirubicin—thyroid cancer	3.43e-05	0.000488	CcSEcCtD
Everolimus—Dysphagia—Doxorubicin—thyroid cancer	3.41e-05	0.000486	CcSEcCtD
Everolimus—Influenza—Doxorubicin—thyroid cancer	3.41e-05	0.000486	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR in Cancer—PTEN—thyroid cancer	3.41e-05	0.0012	CbGpPWpGaD
Everolimus—Pollakiuria—Epirubicin—thyroid cancer	3.41e-05	0.000485	CcSEcCtD
Everolimus—MTOR—Signaling by PDGF—PTEN—thyroid cancer	3.39e-05	0.0012	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—HRAS—thyroid cancer	3.39e-05	0.0012	CbGpPWpGaD
Everolimus—Nausea—Sorafenib—thyroid cancer	3.37e-05	0.00048	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—BRAF—thyroid cancer	3.35e-05	0.00119	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CDK1—thyroid cancer	3.35e-05	0.00119	CbGpPWpGaD
Everolimus—Pancreatitis—Doxorubicin—thyroid cancer	3.34e-05	0.000477	CcSEcCtD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	3.34e-05	0.00118	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—NRAS—thyroid cancer	3.34e-05	0.00118	CbGpPWpGaD
Everolimus—Weight decreased—Epirubicin—thyroid cancer	3.34e-05	0.000475	CcSEcCtD
Everolimus—Hyperglycaemia—Epirubicin—thyroid cancer	3.33e-05	0.000474	CcSEcCtD
Everolimus—Angina pectoris—Doxorubicin—thyroid cancer	3.32e-05	0.000474	CcSEcCtD
Everolimus—MTOR—Signaling by FGFR—NRAS—thyroid cancer	3.32e-05	0.00117	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TSHR—thyroid cancer	3.31e-05	0.00117	CbGpPWpGaD
Everolimus—Pneumonia—Epirubicin—thyroid cancer	3.31e-05	0.000471	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB2—NRAS—thyroid cancer	3.31e-05	0.00117	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—NRAS—thyroid cancer	3.29e-05	0.00116	CbGpPWpGaD
Everolimus—Infestation NOS—Epirubicin—thyroid cancer	3.29e-05	0.000469	CcSEcCtD
Everolimus—Infestation—Epirubicin—thyroid cancer	3.29e-05	0.000469	CcSEcCtD
Everolimus—Bronchitis—Doxorubicin—thyroid cancer	3.28e-05	0.000468	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—PRKAR1A—thyroid cancer	3.26e-05	0.00115	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—NRAS—thyroid cancer	3.24e-05	0.00115	CbGpPWpGaD
Everolimus—Pancytopenia—Doxorubicin—thyroid cancer	3.24e-05	0.000462	CcSEcCtD
Everolimus—Renal failure—Epirubicin—thyroid cancer	3.23e-05	0.000461	CcSEcCtD
Everolimus—MTOR—Innate Immune System—IFNA2—thyroid cancer	3.22e-05	0.00114	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—PTEN—thyroid cancer	3.21e-05	0.00114	CbGpPWpGaD
Everolimus—MTOR—PI-3K cascade—AKT1—thyroid cancer	3.21e-05	0.00113	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CDK1—thyroid cancer	3.2e-05	0.00113	CbGpPWpGaD
Everolimus—Jaundice—Epirubicin—thyroid cancer	3.2e-05	0.000457	CcSEcCtD
Everolimus—Stomatitis—Epirubicin—thyroid cancer	3.2e-05	0.000457	CcSEcCtD
Everolimus—MTOR—Signaling by VEGF—HRAS—thyroid cancer	3.2e-05	0.00113	CbGpPWpGaD
Everolimus—Conjunctivitis—Epirubicin—thyroid cancer	3.19e-05	0.000455	CcSEcCtD
Everolimus—Urinary tract infection—Epirubicin—thyroid cancer	3.19e-05	0.000455	CcSEcCtD
Everolimus—MTOR—Signaling by SCF-KIT—KRAS—thyroid cancer	3.19e-05	0.00113	CbGpPWpGaD
Everolimus—Dysuria—Doxorubicin—thyroid cancer	3.19e-05	0.000455	CcSEcCtD
Everolimus—Neutropenia—Doxorubicin—thyroid cancer	3.19e-05	0.000455	CcSEcCtD
Everolimus—MTOR—Signaling by Insulin receptor—HRAS—thyroid cancer	3.17e-05	0.00112	CbGpPWpGaD
Everolimus—Upper respiratory tract infection—Doxorubicin—thyroid cancer	3.17e-05	0.000452	CcSEcCtD
Everolimus—Pollakiuria—Doxorubicin—thyroid cancer	3.15e-05	0.000449	CcSEcCtD
Everolimus—Haematuria—Epirubicin—thyroid cancer	3.13e-05	0.000447	CcSEcCtD
Everolimus—MTOR—PI3K/AKT activation—AKT1—thyroid cancer	3.13e-05	0.00111	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MEN1—thyroid cancer	3.11e-05	0.0011	CbGpPWpGaD
Everolimus—Hepatobiliary disease—Epirubicin—thyroid cancer	3.11e-05	0.000443	CcSEcCtD
Everolimus—MTOR—GAB1 signalosome—AKT1—thyroid cancer	3.11e-05	0.0011	CbGpPWpGaD
Everolimus—Epistaxis—Epirubicin—thyroid cancer	3.1e-05	0.000442	CcSEcCtD
Everolimus—MTOR—Signaling by FGFR in disease—NRAS—thyroid cancer	3.09e-05	0.00109	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—NRAS—thyroid cancer	3.09e-05	0.00109	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—NRAS—thyroid cancer	3.09e-05	0.00109	CbGpPWpGaD
Everolimus—Weight decreased—Doxorubicin—thyroid cancer	3.09e-05	0.00044	CcSEcCtD
Everolimus—Sinusitis—Epirubicin—thyroid cancer	3.08e-05	0.00044	CcSEcCtD
Everolimus—Hyperglycaemia—Doxorubicin—thyroid cancer	3.08e-05	0.000439	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—PTEN—thyroid cancer	3.07e-05	0.00109	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—NRAS—thyroid cancer	3.07e-05	0.00108	CbGpPWpGaD
Everolimus—Pneumonia—Doxorubicin—thyroid cancer	3.06e-05	0.000436	CcSEcCtD
Everolimus—MTOR—Downstream signaling of activated FGFR—KRAS—thyroid cancer	3.06e-05	0.00108	CbGpPWpGaD
Everolimus—Infestation—Doxorubicin—thyroid cancer	3.04e-05	0.000434	CcSEcCtD
Everolimus—Infestation NOS—Doxorubicin—thyroid cancer	3.04e-05	0.000434	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR in Cancer—NRAS—thyroid cancer	3.04e-05	0.00107	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—AKT1—thyroid cancer	3.04e-05	0.00107	CbGpPWpGaD
Everolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—AKT1—thyroid cancer	3.04e-05	0.00107	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—NRAS—thyroid cancer	3.03e-05	0.00107	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—KRAS—thyroid cancer	3.02e-05	0.00107	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—KRAS—thyroid cancer	3.01e-05	0.00106	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—AKT1—thyroid cancer	2.99e-05	0.00106	CbGpPWpGaD
Everolimus—Renal failure—Doxorubicin—thyroid cancer	2.99e-05	0.000426	CcSEcCtD
Everolimus—Haemoglobin—Epirubicin—thyroid cancer	2.97e-05	0.000423	CcSEcCtD
Everolimus—Stomatitis—Doxorubicin—thyroid cancer	2.96e-05	0.000423	CcSEcCtD
Everolimus—Jaundice—Doxorubicin—thyroid cancer	2.96e-05	0.000423	CcSEcCtD
Everolimus—Rhinitis—Epirubicin—thyroid cancer	2.96e-05	0.000422	CcSEcCtD
Everolimus—Urinary tract infection—Doxorubicin—thyroid cancer	2.96e-05	0.000421	CcSEcCtD
Everolimus—Conjunctivitis—Doxorubicin—thyroid cancer	2.96e-05	0.000421	CcSEcCtD
Everolimus—Haemorrhage—Epirubicin—thyroid cancer	2.95e-05	0.000421	CcSEcCtD
Everolimus—Hepatitis—Epirubicin—thyroid cancer	2.95e-05	0.000421	CcSEcCtD
Everolimus—Hypoaesthesia—Epirubicin—thyroid cancer	2.94e-05	0.000419	CcSEcCtD
Everolimus—Pharyngitis—Epirubicin—thyroid cancer	2.93e-05	0.000417	CcSEcCtD
Everolimus—Urinary tract disorder—Epirubicin—thyroid cancer	2.91e-05	0.000415	CcSEcCtD
Everolimus—Oedema peripheral—Epirubicin—thyroid cancer	2.91e-05	0.000414	CcSEcCtD
Everolimus—Haematuria—Doxorubicin—thyroid cancer	2.9e-05	0.000413	CcSEcCtD
Everolimus—Connective tissue disorder—Epirubicin—thyroid cancer	2.9e-05	0.000413	CcSEcCtD
Everolimus—Urethral disorder—Epirubicin—thyroid cancer	2.89e-05	0.000412	CcSEcCtD
Everolimus—MTOR—Immune System—TPR—thyroid cancer	2.88e-05	0.00102	CbGpPWpGaD
Everolimus—Hepatobiliary disease—Doxorubicin—thyroid cancer	2.88e-05	0.00041	CcSEcCtD
Everolimus—MTOR—Downstream signal transduction—KRAS—thyroid cancer	2.87e-05	0.00102	CbGpPWpGaD
Everolimus—Epistaxis—Doxorubicin—thyroid cancer	2.87e-05	0.000409	CcSEcCtD
Everolimus—MTOR—B Cell Activation—NRAS—thyroid cancer	2.86e-05	0.00101	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—KRAS—thyroid cancer	2.86e-05	0.00101	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—KRAS—thyroid cancer	2.86e-05	0.00101	CbGpPWpGaD
Everolimus—MTOR—Immune System—LGALS3—thyroid cancer	2.86e-05	0.00101	CbGpPWpGaD
Everolimus—Sinusitis—Doxorubicin—thyroid cancer	2.85e-05	0.000407	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB2—KRAS—thyroid cancer	2.84e-05	0.00101	CbGpPWpGaD
Everolimus—MTOR—Immune System—PRKAR1A—thyroid cancer	2.83e-05	0.001	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—KRAS—thyroid cancer	2.83e-05	0.001	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—AKT1—thyroid cancer	2.82e-05	0.000998	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PTCH1—thyroid cancer	2.82e-05	0.000996	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KRAS—thyroid cancer	2.79e-05	0.000987	CbGpPWpGaD
Everolimus—Eye disorder—Epirubicin—thyroid cancer	2.76e-05	0.000393	CcSEcCtD
Everolimus—Haemoglobin—Doxorubicin—thyroid cancer	2.74e-05	0.000391	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NRAS—thyroid cancer	2.74e-05	0.000969	CbGpPWpGaD
Everolimus—Flushing—Epirubicin—thyroid cancer	2.74e-05	0.00039	CcSEcCtD
Everolimus—Cardiac disorder—Epirubicin—thyroid cancer	2.74e-05	0.00039	CcSEcCtD
Everolimus—Rhinitis—Doxorubicin—thyroid cancer	2.74e-05	0.00039	CcSEcCtD
Everolimus—Hepatitis—Doxorubicin—thyroid cancer	2.73e-05	0.000389	CcSEcCtD
Everolimus—Haemorrhage—Doxorubicin—thyroid cancer	2.73e-05	0.000389	CcSEcCtD
Everolimus—Hypoaesthesia—Doxorubicin—thyroid cancer	2.72e-05	0.000387	CcSEcCtD
Everolimus—MTOR—Signaling by SCF-KIT—HRAS—thyroid cancer	2.72e-05	0.00096	CbGpPWpGaD
Everolimus—Pharyngitis—Doxorubicin—thyroid cancer	2.71e-05	0.000386	CcSEcCtD
Everolimus—Urinary tract disorder—Doxorubicin—thyroid cancer	2.7e-05	0.000384	CcSEcCtD
Everolimus—MTOR—Innate Immune System—NRG1—thyroid cancer	2.69e-05	0.000951	CbGpPWpGaD
Everolimus—Oedema peripheral—Doxorubicin—thyroid cancer	2.69e-05	0.000383	CcSEcCtD
Everolimus—MTOR—Integrated Breast Cancer Pathway—TP53—thyroid cancer	2.69e-05	0.000951	CbGpPWpGaD
Everolimus—Connective tissue disorder—Doxorubicin—thyroid cancer	2.68e-05	0.000382	CcSEcCtD
Everolimus—Angiopathy—Epirubicin—thyroid cancer	2.68e-05	0.000382	CcSEcCtD
Everolimus—Urethral disorder—Doxorubicin—thyroid cancer	2.68e-05	0.000382	CcSEcCtD
Everolimus—MTOR—BDNF signaling pathway—HRAS—thyroid cancer	2.67e-05	0.000944	CbGpPWpGaD
Everolimus—Immune system disorder—Epirubicin—thyroid cancer	2.67e-05	0.00038	CcSEcCtD
Everolimus—MTOR—DAP12 interactions—KRAS—thyroid cancer	2.66e-05	0.000942	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KRAS—thyroid cancer	2.66e-05	0.000942	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—KRAS—thyroid cancer	2.66e-05	0.000942	CbGpPWpGaD
Everolimus—MTOR—Disease—TPR—thyroid cancer	2.66e-05	0.000941	CbGpPWpGaD
Everolimus—Mediastinal disorder—Epirubicin—thyroid cancer	2.66e-05	0.000379	CcSEcCtD
Everolimus—Chills—Epirubicin—thyroid cancer	2.65e-05	0.000377	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR—KRAS—thyroid cancer	2.64e-05	0.000933	CbGpPWpGaD
Everolimus—MTOR—Disease—PRKAR1A—thyroid cancer	2.62e-05	0.000925	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—KRAS—thyroid cancer	2.62e-05	0.000925	CbGpPWpGaD
Everolimus—Alopecia—Epirubicin—thyroid cancer	2.61e-05	0.000372	CcSEcCtD
Everolimus—MTOR—Signaling by PDGF—KRAS—thyroid cancer	2.6e-05	0.000921	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—HRAS—thyroid cancer	2.6e-05	0.000919	CbGpPWpGaD
Everolimus—Mental disorder—Epirubicin—thyroid cancer	2.59e-05	0.000369	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—NRG1—thyroid cancer	2.58e-05	0.000914	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SST—thyroid cancer	2.58e-05	0.000911	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NRG1—thyroid cancer	2.57e-05	0.00091	CbGpPWpGaD
Everolimus—Malnutrition—Epirubicin—thyroid cancer	2.57e-05	0.000366	CcSEcCtD
Everolimus—Erythema—Epirubicin—thyroid cancer	2.57e-05	0.000366	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB4—HRAS—thyroid cancer	2.56e-05	0.000904	CbGpPWpGaD
Everolimus—Eye disorder—Doxorubicin—thyroid cancer	2.55e-05	0.000364	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—TCF7L1—thyroid cancer	2.54e-05	0.0009	CbGpPWpGaD
Everolimus—Cardiac disorder—Doxorubicin—thyroid cancer	2.53e-05	0.000361	CcSEcCtD
Everolimus—Flushing—Doxorubicin—thyroid cancer	2.53e-05	0.000361	CcSEcCtD
Everolimus—Flatulence—Epirubicin—thyroid cancer	2.53e-05	0.000361	CcSEcCtD
Everolimus—Dysgeusia—Epirubicin—thyroid cancer	2.52e-05	0.000359	CcSEcCtD
Everolimus—MTOR—Disease—MEN1—thyroid cancer	2.5e-05	0.000884	CbGpPWpGaD
Everolimus—Back pain—Epirubicin—thyroid cancer	2.48e-05	0.000354	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—CALCA—thyroid cancer	2.48e-05	0.000877	CbGpPWpGaD
Everolimus—Angiopathy—Doxorubicin—thyroid cancer	2.48e-05	0.000353	CcSEcCtD
Everolimus—Muscle spasms—Epirubicin—thyroid cancer	2.47e-05	0.000352	CcSEcCtD
Everolimus—Immune system disorder—Doxorubicin—thyroid cancer	2.47e-05	0.000352	CcSEcCtD
Everolimus—MTOR—B Cell Activation—KRAS—thyroid cancer	2.46e-05	0.000872	CbGpPWpGaD
Everolimus—Mediastinal disorder—Doxorubicin—thyroid cancer	2.46e-05	0.000351	CcSEcCtD
Everolimus—MTOR—Insulin Signaling—HRAS—thyroid cancer	2.45e-05	0.000868	CbGpPWpGaD
Everolimus—Chills—Doxorubicin—thyroid cancer	2.45e-05	0.000349	CcSEcCtD
Everolimus—MTOR—Downstream signal transduction—HRAS—thyroid cancer	2.44e-05	0.000864	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—thyroid cancer	2.43e-05	0.000859	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—HRAS—thyroid cancer	2.43e-05	0.000859	CbGpPWpGaD
Everolimus—Vision blurred—Epirubicin—thyroid cancer	2.42e-05	0.000345	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB2—HRAS—thyroid cancer	2.42e-05	0.000855	CbGpPWpGaD
Everolimus—Alopecia—Doxorubicin—thyroid cancer	2.41e-05	0.000344	CcSEcCtD
Everolimus—MTOR—DAP12 signaling—HRAS—thyroid cancer	2.41e-05	0.000851	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—AKT1—thyroid cancer	2.4e-05	0.000848	CbGpPWpGaD
Everolimus—Mental disorder—Doxorubicin—thyroid cancer	2.39e-05	0.000341	CcSEcCtD
Everolimus—Ill-defined disorder—Epirubicin—thyroid cancer	2.38e-05	0.00034	CcSEcCtD
Everolimus—Erythema—Doxorubicin—thyroid cancer	2.38e-05	0.000339	CcSEcCtD
Everolimus—Malnutrition—Doxorubicin—thyroid cancer	2.38e-05	0.000339	CcSEcCtD
Everolimus—Anaemia—Epirubicin—thyroid cancer	2.37e-05	0.000338	CcSEcCtD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—thyroid cancer	2.37e-05	0.000839	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—PTEN—thyroid cancer	2.36e-05	0.000836	CbGpPWpGaD
Everolimus—Agitation—Epirubicin—thyroid cancer	2.36e-05	0.000336	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KRAS—thyroid cancer	2.36e-05	0.000834	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—AKT1—thyroid cancer	2.36e-05	0.000834	CbGpPWpGaD
Everolimus—Flatulence—Doxorubicin—thyroid cancer	2.34e-05	0.000334	CcSEcCtD
Everolimus—Dysgeusia—Doxorubicin—thyroid cancer	2.33e-05	0.000332	CcSEcCtD
Everolimus—Malaise—Epirubicin—thyroid cancer	2.32e-05	0.00033	CcSEcCtD
Everolimus—FKBP1A—Disease—TERT—thyroid cancer	2.31e-05	0.000817	CbGpPWpGaD
Everolimus—Syncope—Epirubicin—thyroid cancer	2.3e-05	0.000328	CcSEcCtD
Everolimus—Leukopenia—Epirubicin—thyroid cancer	2.3e-05	0.000328	CcSEcCtD
Everolimus—Back pain—Doxorubicin—thyroid cancer	2.3e-05	0.000328	CcSEcCtD
Everolimus—MTOR—Downstream signaling of activated FGFR—AKT1—thyroid cancer	2.29e-05	0.000811	CbGpPWpGaD
Everolimus—Muscle spasms—Doxorubicin—thyroid cancer	2.29e-05	0.000326	CcSEcCtD
Everolimus—Palpitations—Epirubicin—thyroid cancer	2.27e-05	0.000324	CcSEcCtD
Everolimus—MTOR—Integrated Breast Cancer Pathway—AKT1—thyroid cancer	2.27e-05	0.000803	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—HRAS—thyroid cancer	2.26e-05	0.000801	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—HRAS—thyroid cancer	2.26e-05	0.000801	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—thyroid cancer	2.26e-05	0.000801	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—AKT1—thyroid cancer	2.26e-05	0.000798	CbGpPWpGaD
Everolimus—Loss of consciousness—Epirubicin—thyroid cancer	2.26e-05	0.000322	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—CDK1—thyroid cancer	2.24e-05	0.000794	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—HRAS—thyroid cancer	2.24e-05	0.000793	CbGpPWpGaD
Everolimus—Cough—Epirubicin—thyroid cancer	2.24e-05	0.00032	CcSEcCtD
Everolimus—Vision blurred—Doxorubicin—thyroid cancer	2.24e-05	0.000319	CcSEcCtD
Everolimus—Convulsion—Epirubicin—thyroid cancer	2.23e-05	0.000317	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR in Cancer—HRAS—thyroid cancer	2.22e-05	0.000786	CbGpPWpGaD
Everolimus—Hypertension—Epirubicin—thyroid cancer	2.22e-05	0.000316	CcSEcCtD
Everolimus—MTOR—Signaling by PDGF—HRAS—thyroid cancer	2.21e-05	0.000783	CbGpPWpGaD
Everolimus—FKBP1A—Disease—HIF1A—thyroid cancer	2.21e-05	0.000781	CbGpPWpGaD
Everolimus—Ill-defined disorder—Doxorubicin—thyroid cancer	2.21e-05	0.000314	CcSEcCtD
Everolimus—Anaemia—Doxorubicin—thyroid cancer	2.2e-05	0.000313	CcSEcCtD
Everolimus—Myalgia—Epirubicin—thyroid cancer	2.19e-05	0.000312	CcSEcCtD
Everolimus—Arthralgia—Epirubicin—thyroid cancer	2.19e-05	0.000312	CcSEcCtD
Everolimus—Chest pain—Epirubicin—thyroid cancer	2.19e-05	0.000312	CcSEcCtD
Everolimus—Agitation—Doxorubicin—thyroid cancer	2.18e-05	0.000311	CcSEcCtD
Everolimus—Anxiety—Epirubicin—thyroid cancer	2.18e-05	0.000311	CcSEcCtD
Everolimus—CYP3A4—Biological oxidations—RXRA—thyroid cancer	2.17e-05	0.000769	CbGpPWpGaD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	2.17e-05	0.00031	CcSEcCtD
Everolimus—MTOR—Insulin Signaling—AKT1—thyroid cancer	2.17e-05	0.000766	CbGpPWpGaD
Everolimus—Discomfort—Epirubicin—thyroid cancer	2.16e-05	0.000308	CcSEcCtD
Everolimus—MTOR—Downstream signal transduction—AKT1—thyroid cancer	2.16e-05	0.000763	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—AKT1—thyroid cancer	2.15e-05	0.000759	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—AKT1—thyroid cancer	2.15e-05	0.000759	CbGpPWpGaD
Everolimus—Malaise—Doxorubicin—thyroid cancer	2.14e-05	0.000306	CcSEcCtD
Everolimus—Dry mouth—Epirubicin—thyroid cancer	2.14e-05	0.000305	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB2—AKT1—thyroid cancer	2.14e-05	0.000755	CbGpPWpGaD
Everolimus—Syncope—Doxorubicin—thyroid cancer	2.13e-05	0.000304	CcSEcCtD
Everolimus—Leukopenia—Doxorubicin—thyroid cancer	2.13e-05	0.000303	CcSEcCtD
Everolimus—MTOR—DAP12 signaling—AKT1—thyroid cancer	2.12e-05	0.000751	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—NRAS—thyroid cancer	2.11e-05	0.000745	CbGpPWpGaD
Everolimus—Palpitations—Doxorubicin—thyroid cancer	2.1e-05	0.000299	CcSEcCtD
Everolimus—Oedema—Epirubicin—thyroid cancer	2.1e-05	0.000299	CcSEcCtD
Everolimus—MTOR—B Cell Activation—HRAS—thyroid cancer	2.09e-05	0.000741	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—thyroid cancer	2.09e-05	0.000741	CbGpPWpGaD
Everolimus—Loss of consciousness—Doxorubicin—thyroid cancer	2.09e-05	0.000298	CcSEcCtD
Everolimus—Infection—Epirubicin—thyroid cancer	2.08e-05	0.000297	CcSEcCtD
Everolimus—Cough—Doxorubicin—thyroid cancer	2.07e-05	0.000296	CcSEcCtD
Everolimus—Shock—Epirubicin—thyroid cancer	2.06e-05	0.000294	CcSEcCtD
Everolimus—Convulsion—Doxorubicin—thyroid cancer	2.06e-05	0.000294	CcSEcCtD
Everolimus—Nervous system disorder—Epirubicin—thyroid cancer	2.06e-05	0.000293	CcSEcCtD
Everolimus—Thrombocytopenia—Epirubicin—thyroid cancer	2.05e-05	0.000293	CcSEcCtD
Everolimus—Hypertension—Doxorubicin—thyroid cancer	2.05e-05	0.000293	CcSEcCtD
Everolimus—Tachycardia—Epirubicin—thyroid cancer	2.05e-05	0.000292	CcSEcCtD
Everolimus—Skin disorder—Epirubicin—thyroid cancer	2.04e-05	0.00029	CcSEcCtD
Everolimus—Hyperhidrosis—Epirubicin—thyroid cancer	2.03e-05	0.000289	CcSEcCtD
Everolimus—Chest pain—Doxorubicin—thyroid cancer	2.02e-05	0.000288	CcSEcCtD
Everolimus—Myalgia—Doxorubicin—thyroid cancer	2.02e-05	0.000288	CcSEcCtD
Everolimus—Arthralgia—Doxorubicin—thyroid cancer	2.02e-05	0.000288	CcSEcCtD
Everolimus—Anxiety—Doxorubicin—thyroid cancer	2.02e-05	0.000287	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	2.01e-05	0.000286	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—thyroid cancer	2e-05	0.000709	CbGpPWpGaD
Everolimus—Discomfort—Doxorubicin—thyroid cancer	2e-05	0.000285	CcSEcCtD
Everolimus—MTOR—Signaling by FGFR in disease—AKT1—thyroid cancer	2e-05	0.000707	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—thyroid cancer	2e-05	0.000707	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—AKT1—thyroid cancer	2e-05	0.000707	CbGpPWpGaD
Everolimus—Anorexia—Epirubicin—thyroid cancer	2e-05	0.000285	CcSEcCtD
Everolimus—MTOR—Disease—CALCA—thyroid cancer	1.99e-05	0.000704	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—AKT1—thyroid cancer	1.98e-05	0.000701	CbGpPWpGaD
Everolimus—Dry mouth—Doxorubicin—thyroid cancer	1.98e-05	0.000282	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR in Cancer—AKT1—thyroid cancer	1.96e-05	0.000694	CbGpPWpGaD
Everolimus—Hypotension—Epirubicin—thyroid cancer	1.96e-05	0.000279	CcSEcCtD
Everolimus—MTOR—Signaling by PDGF—AKT1—thyroid cancer	1.95e-05	0.000691	CbGpPWpGaD
Everolimus—MTOR—Immune System—CDK1—thyroid cancer	1.95e-05	0.00069	CbGpPWpGaD
Everolimus—Oedema—Doxorubicin—thyroid cancer	1.94e-05	0.000277	CcSEcCtD
Everolimus—Infection—Doxorubicin—thyroid cancer	1.93e-05	0.000275	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Epirubicin—thyroid cancer	1.91e-05	0.000272	CcSEcCtD
Everolimus—Shock—Doxorubicin—thyroid cancer	1.91e-05	0.000272	CcSEcCtD
Everolimus—Nervous system disorder—Doxorubicin—thyroid cancer	1.9e-05	0.000271	CcSEcCtD
Everolimus—Thrombocytopenia—Doxorubicin—thyroid cancer	1.9e-05	0.000271	CcSEcCtD
Everolimus—Insomnia—Epirubicin—thyroid cancer	1.9e-05	0.00027	CcSEcCtD
Everolimus—Tachycardia—Doxorubicin—thyroid cancer	1.89e-05	0.00027	CcSEcCtD
Everolimus—Skin disorder—Doxorubicin—thyroid cancer	1.88e-05	0.000269	CcSEcCtD
Everolimus—Paraesthesia—Epirubicin—thyroid cancer	1.88e-05	0.000268	CcSEcCtD
Everolimus—MTOR—Immune System—IFNA2—thyroid cancer	1.88e-05	0.000664	CbGpPWpGaD
Everolimus—Hyperhidrosis—Doxorubicin—thyroid cancer	1.88e-05	0.000267	CcSEcCtD
Everolimus—Dyspnoea—Epirubicin—thyroid cancer	1.87e-05	0.000266	CcSEcCtD
Everolimus—Somnolence—Epirubicin—thyroid cancer	1.86e-05	0.000266	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—TSHR—thyroid cancer	1.86e-05	0.000659	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—AKT1—thyroid cancer	1.85e-05	0.000654	CbGpPWpGaD
Everolimus—Anorexia—Doxorubicin—thyroid cancer	1.85e-05	0.000264	CcSEcCtD
Everolimus—Dyspepsia—Epirubicin—thyroid cancer	1.85e-05	0.000263	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—PRKAR1A—thyroid cancer	1.83e-05	0.000648	CbGpPWpGaD
Everolimus—FKBP1A—Disease—BRAF—thyroid cancer	1.83e-05	0.000647	CbGpPWpGaD
Everolimus—Decreased appetite—Epirubicin—thyroid cancer	1.82e-05	0.00026	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—KRAS—thyroid cancer	1.81e-05	0.000642	CbGpPWpGaD
Everolimus—Hypotension—Doxorubicin—thyroid cancer	1.81e-05	0.000258	CcSEcCtD
Everolimus—Gastrointestinal disorder—Epirubicin—thyroid cancer	1.81e-05	0.000258	CcSEcCtD
Everolimus—Fatigue—Epirubicin—thyroid cancer	1.81e-05	0.000258	CcSEcCtD
Everolimus—MTOR—Disease—CDK1—thyroid cancer	1.8e-05	0.000637	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NRG1—thyroid cancer	1.8e-05	0.000637	CbGpPWpGaD
Everolimus—Pain—Epirubicin—thyroid cancer	1.79e-05	0.000256	CcSEcCtD
Everolimus—Constipation—Epirubicin—thyroid cancer	1.79e-05	0.000256	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—thyroid cancer	1.77e-05	0.000626	CbGpPWpGaD
Everolimus—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	1.77e-05	0.000252	CcSEcCtD
Everolimus—Insomnia—Doxorubicin—thyroid cancer	1.75e-05	0.00025	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—MEN1—thyroid cancer	1.75e-05	0.000619	CbGpPWpGaD
Everolimus—Paraesthesia—Doxorubicin—thyroid cancer	1.74e-05	0.000248	CcSEcCtD
Everolimus—Dyspnoea—Doxorubicin—thyroid cancer	1.73e-05	0.000247	CcSEcCtD
Everolimus—Feeling abnormal—Epirubicin—thyroid cancer	1.73e-05	0.000246	CcSEcCtD
Everolimus—Somnolence—Doxorubicin—thyroid cancer	1.72e-05	0.000246	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—TP53—thyroid cancer	1.72e-05	0.000608	CbGpPWpGaD
Everolimus—Gastrointestinal pain—Epirubicin—thyroid cancer	1.71e-05	0.000244	CcSEcCtD
Everolimus—Dyspepsia—Doxorubicin—thyroid cancer	1.71e-05	0.000243	CcSEcCtD
Everolimus—Decreased appetite—Doxorubicin—thyroid cancer	1.69e-05	0.00024	CcSEcCtD
Everolimus—Gastrointestinal disorder—Doxorubicin—thyroid cancer	1.67e-05	0.000239	CcSEcCtD
Everolimus—Fatigue—Doxorubicin—thyroid cancer	1.67e-05	0.000238	CcSEcCtD
Everolimus—Constipation—Doxorubicin—thyroid cancer	1.66e-05	0.000236	CcSEcCtD
Everolimus—Pain—Doxorubicin—thyroid cancer	1.66e-05	0.000236	CcSEcCtD
Everolimus—Body temperature increased—Epirubicin—thyroid cancer	1.66e-05	0.000236	CcSEcCtD
Everolimus—Abdominal pain—Epirubicin—thyroid cancer	1.66e-05	0.000236	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—TERT—thyroid cancer	1.62e-05	0.000572	CbGpPWpGaD
Everolimus—Feeling abnormal—Doxorubicin—thyroid cancer	1.6e-05	0.000228	CcSEcCtD
Everolimus—CYP3A4—Metabolism—MINPP1—thyroid cancer	1.6e-05	0.000565	CbGpPWpGaD
Everolimus—Gastrointestinal pain—Doxorubicin—thyroid cancer	1.59e-05	0.000226	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—PTCH1—thyroid cancer	1.58e-05	0.00056	CbGpPWpGaD
Everolimus—MTOR—Immune System—NRG1—thyroid cancer	1.57e-05	0.000554	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—HIF1A—thyroid cancer	1.55e-05	0.000547	CbGpPWpGaD
Everolimus—Hypersensitivity—Epirubicin—thyroid cancer	1.54e-05	0.00022	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—HRAS—thyroid cancer	1.54e-05	0.000545	CbGpPWpGaD
Everolimus—Body temperature increased—Doxorubicin—thyroid cancer	1.53e-05	0.000219	CcSEcCtD
Everolimus—Abdominal pain—Doxorubicin—thyroid cancer	1.53e-05	0.000219	CcSEcCtD
Everolimus—Asthenia—Epirubicin—thyroid cancer	1.5e-05	0.000214	CcSEcCtD
Everolimus—Pruritus—Epirubicin—thyroid cancer	1.48e-05	0.000211	CcSEcCtD
Everolimus—FKBP1A—Disease—PTGS2—thyroid cancer	1.48e-05	0.000523	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SST—thyroid cancer	1.45e-05	0.000512	CbGpPWpGaD
Everolimus—MTOR—Disease—NRG1—thyroid cancer	1.45e-05	0.000512	CbGpPWpGaD
Everolimus—Diarrhoea—Epirubicin—thyroid cancer	1.43e-05	0.000204	CcSEcCtD
Everolimus—Hypersensitivity—Doxorubicin—thyroid cancer	1.43e-05	0.000204	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—CALCA—thyroid cancer	1.39e-05	0.000493	CbGpPWpGaD
Everolimus—Asthenia—Doxorubicin—thyroid cancer	1.39e-05	0.000198	CcSEcCtD
Everolimus—Dizziness—Epirubicin—thyroid cancer	1.39e-05	0.000198	CcSEcCtD
Everolimus—Pruritus—Doxorubicin—thyroid cancer	1.37e-05	0.000196	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—AKT1—thyroid cancer	1.36e-05	0.000482	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NDUFA13—thyroid cancer	1.36e-05	0.00048	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—PTEN—thyroid cancer	1.35e-05	0.000477	CbGpPWpGaD
Everolimus—Vomiting—Epirubicin—thyroid cancer	1.33e-05	0.00019	CcSEcCtD
Everolimus—Diarrhoea—Doxorubicin—thyroid cancer	1.33e-05	0.000189	CcSEcCtD
Everolimus—Rash—Epirubicin—thyroid cancer	1.32e-05	0.000188	CcSEcCtD
Everolimus—Dermatitis—Epirubicin—thyroid cancer	1.32e-05	0.000188	CcSEcCtD
Everolimus—Headache—Epirubicin—thyroid cancer	1.31e-05	0.000187	CcSEcCtD
Everolimus—MTOR—Disease—TERT—thyroid cancer	1.3e-05	0.000459	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PTEN—thyroid cancer	1.29e-05	0.000458	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PTEN—thyroid cancer	1.29e-05	0.000456	CbGpPWpGaD
Everolimus—Dizziness—Doxorubicin—thyroid cancer	1.28e-05	0.000183	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—BRAF—thyroid cancer	1.28e-05	0.000453	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CHST14—thyroid cancer	1.28e-05	0.000451	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CDK1—thyroid cancer	1.26e-05	0.000446	CbGpPWpGaD
Everolimus—Nausea—Epirubicin—thyroid cancer	1.25e-05	0.000178	CcSEcCtD
Everolimus—MTOR—Disease—HIF1A—thyroid cancer	1.24e-05	0.000439	CbGpPWpGaD
Everolimus—Vomiting—Doxorubicin—thyroid cancer	1.23e-05	0.000176	CcSEcCtD
Everolimus—Rash—Doxorubicin—thyroid cancer	1.22e-05	0.000174	CcSEcCtD
Everolimus—Dermatitis—Doxorubicin—thyroid cancer	1.22e-05	0.000174	CcSEcCtD
Everolimus—Headache—Doxorubicin—thyroid cancer	1.22e-05	0.000173	CcSEcCtD
Everolimus—MTOR—Innate Immune System—NRAS—thyroid cancer	1.2e-05	0.000425	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—NRAS—thyroid cancer	1.15e-05	0.000408	CbGpPWpGaD
Everolimus—Nausea—Doxorubicin—thyroid cancer	1.15e-05	0.000164	CcSEcCtD
Everolimus—FKBP1A—Disease—NRAS—thyroid cancer	1.15e-05	0.000407	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—KRAS—thyroid cancer	1.03e-05	0.000366	CbGpPWpGaD
Everolimus—MTOR—Disease—BRAF—thyroid cancer	1.03e-05	0.000364	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HPGD—thyroid cancer	1.03e-05	0.000364	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NRG1—thyroid cancer	1.01e-05	0.000358	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—KRAS—thyroid cancer	9.94e-06	0.000351	CbGpPWpGaD
Everolimus—FKBP1A—Disease—KRAS—thyroid cancer	9.89e-06	0.00035	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCND1—thyroid cancer	9.35e-06	0.000331	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TERT—thyroid cancer	9.1e-06	0.000322	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PTEN—thyroid cancer	9.02e-06	0.000319	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—HRAS—thyroid cancer	8.8e-06	0.000311	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HIF1A—thyroid cancer	8.7e-06	0.000308	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—HRAS—thyroid cancer	8.45e-06	0.000299	CbGpPWpGaD
Everolimus—FKBP1A—Disease—HRAS—thyroid cancer	8.41e-06	0.000297	CbGpPWpGaD
Everolimus—MTOR—Disease—PTGS2—thyroid cancer	8.31e-06	0.000294	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NRAS—thyroid cancer	8.05e-06	0.000285	CbGpPWpGaD
Everolimus—MTOR—Immune System—PTEN—thyroid cancer	7.85e-06	0.000278	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—AKT1—thyroid cancer	7.77e-06	0.000275	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—AKT1—thyroid cancer	7.46e-06	0.000264	CbGpPWpGaD
Everolimus—FKBP1A—Disease—AKT1—thyroid cancer	7.43e-06	0.000263	CbGpPWpGaD
Everolimus—MTOR—Disease—PTEN—thyroid cancer	7.25e-06	0.000256	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—BRAF—thyroid cancer	7.2e-06	0.000255	CbGpPWpGaD
Everolimus—MTOR—Immune System—NRAS—thyroid cancer	7e-06	0.000248	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—KRAS—thyroid cancer	6.93e-06	0.000245	CbGpPWpGaD
Everolimus—MTOR—Disease—NRAS—thyroid cancer	6.47e-06	0.000229	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TP53—thyroid cancer	6.16e-06	0.000218	CbGpPWpGaD
Everolimus—MTOR—Immune System—KRAS—thyroid cancer	6.03e-06	0.000213	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—TPR—thyroid cancer	5.91e-06	0.000209	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—HRAS—thyroid cancer	5.89e-06	0.000208	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	5.81e-06	0.000206	CbGpPWpGaD
Everolimus—MTOR—Disease—KRAS—thyroid cancer	5.56e-06	0.000197	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCND1—thyroid cancer	5.26e-06	0.000186	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AKT1—thyroid cancer	5.2e-06	0.000184	CbGpPWpGaD
Everolimus—MTOR—Immune System—HRAS—thyroid cancer	5.12e-06	0.000181	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PTEN—thyroid cancer	5.07e-06	0.000179	CbGpPWpGaD
Everolimus—MTOR—Disease—HRAS—thyroid cancer	4.73e-06	0.000167	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NRAS—thyroid cancer	4.53e-06	0.00016	CbGpPWpGaD
Everolimus—MTOR—Immune System—AKT1—thyroid cancer	4.52e-06	0.00016	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SLC5A5—thyroid cancer	4.42e-06	0.000156	CbGpPWpGaD
Everolimus—MTOR—Disease—AKT1—thyroid cancer	4.18e-06	0.000148	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KRAS—thyroid cancer	3.9e-06	0.000138	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—RXRA—thyroid cancer	3.72e-06	0.000131	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TP53—thyroid cancer	3.46e-06	0.000122	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HRAS—thyroid cancer	3.31e-06	0.000117	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AKT1—thyroid cancer	2.92e-06	0.000103	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PPARG—thyroid cancer	2.35e-06	8.3e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTGS2—thyroid cancer	1.85e-06	6.53e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTEN—thyroid cancer	1.61e-06	5.69e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AKT1—thyroid cancer	9.28e-07	3.28e-05	CbGpPWpGaD
